Spotlight on Cardiovascular VC Funding In 1st Half 2006
Atrial fibrillation is the hottest sector among five highly dynamic areas within cardiovascular technology, according to an analysis by cvPipeline.
You may also be interested in...
A solid foundation has been laid in the field of devices for atrial fibrillation; clinical trials have underscored the efficacy of cardiac ablation devices compared to drugs, reimbursement is in place for both surgical and catheter-based ablation procedures, and large companies have invested heavily in the technologies, validating the entire field. Early devices on the market are bringing in some revenues for their developers, but much remains to be done before atrial fibrillation becomes the multi-billion market everyone talks about. The biggest challenge that lies ahead: clinical trials, for today, all ablation devices are used off-label for atrial fibrillation.
Proteus Biomedical Inc. is developing a suite of proprietary MEMS-based technologies for congestive heart failure. It is staking its first claim in the fast-growing cardiac resynchronization therapy market.
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.